Literature DB >> 14961555

Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population.

Mayumi Saeki1, Yoshiro Saito, Takahiro Nakamura, Norie Murayama, Su-Ryang Kim, Shogo Ozawa, Kazuo Komamura, Kazuyuki Ueno, Shiro Kamakura, Toshiharu Nakajima, Hirohisa Saito, Yutaka Kitamura, Naoyuki Kamatani, Jun-ichi Sawada.   

Abstract

In order to identify single nucleotide polymorphisms (SNPs) and haplotype frequencies of CYP3A5 in a Japanese population, we sequenced the proximal promoter region, all exons, and the surrounding intronic regions using genomic DNA from 187 Japanese subjects. Thirteen SNPs, including seven novel ones: 13108T>C, 16025A>G, 16903A>G, 16993C>G, 27448C>A, 29782A>G, and 31551T>C (A of the translational start codon of GenBank Accession # NG_000004.2 is numbered 1 according to the CYP Allele Nomenclature), were identified. The most common SNP was 6986A>G (key SNP for CYP3A5*3), with a 0.759 frequency. Two novel SNPs, 29782A>G (I456V) and 31551T>C (I488T), as well as 12952T>C (*5 marker) were found, but these alterations were always associated with the *3A marker SNPs, 6986A>G and 31611C>T. Using these 13 SNPs, haplotype analysis was performed and five novel *1 haplotypes (subtypes) (*1e to *1i) and six novel *3 haplotypes (subtypes) (*3d to *3i) were identified. Our findings suggest that CYP3A5*3 is the major defective allele and that other functional exonic SNPs are rare in the Japanese. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14961555     DOI: 10.1002/humu.9147

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  11 in total

1.  Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.

Authors:  Su-Jun Lee; William J Jusko; Christine G Salaita; Karim A Calis; Michael W Jann; Vicky E Spratlin; Joyce A Goldstein; Yuen Yi Hon
Journal:  J Clin Pharmacol       Date:  2006-05       Impact factor: 3.126

Review 2.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system.

Authors:  Su-Jun Lee; Ilse P van der Heiden; Joyce A Goldstein; Ron H N van Schaik
Journal:  Drug Metab Dispos       Date:  2006-10-11       Impact factor: 3.922

Review 4.  Significance of the minor cytochrome P450 3A isoforms.

Authors:  Ann K Daly
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.

Authors:  Ji H Choi; Yoon J Lee; Seong B Jang; Jong-Eun Lee; Kyung H Kim; Kyungsoo Park
Journal:  Br J Clin Pharmacol       Date:  2007-03-28       Impact factor: 4.335

Review 6.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

7.  Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations.

Authors:  Tadahiro Hashita; Yoshihiko Katsuyama; Katsunori Nakamura; Yasuyuki Momose; Daisuke Komatsu; Naohiko Koide; Shinichi Miyagawa; Tomonori Nakamura; Koujirou Yamamoto; Shigeru Ohmori
Journal:  Oncol Lett       Date:  2012-06-28       Impact factor: 2.967

Review 8.  Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.

Authors:  Ogheneochukome Lolodi; Yue-Ming Wang; William C Wright; Taosheng Chen
Journal:  Curr Drug Metab       Date:  2017       Impact factor: 3.731

Review 9.  PharmVar GeneFocus: CYP3A5.

Authors:  Cristina Rodriguez-Antona; Jessica L Savieo; Volker M Lauschke; Katrin Sangkuhl; Britt I Drögemöller; Danxin Wang; Ron H N van Schaik; Andrei A Gilep; Arul P Peter; Erin C Boone; Bronwyn E Ramey; Teri E Klein; Michelle Whirl-Carrillo; Victoria M Pratt; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2022-02-24       Impact factor: 6.903

10.  Effects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMs.

Authors:  Katsuyoshi Sugimoto; Tsukasa Uno; Tomonori Tateishi
Journal:  Eur J Clin Pharmacol       Date:  2008-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.